Stock IdeasStrong Buy StocksStrong Buy Stocks from Top Wall Street AnalystsLatest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen
Stock IdeasStrong Buy Stocks
| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Oruka Therapeutics IncORKA | $40.00 | Strong Buy | $50.00 | +25.00% | 16 hours ago | |
Analyst RankingTop 2% #92 out of 5217 analysts Average Return+34.87% Win Rate52%85 out of 163 Risk vs RewardPoor Good Analyst ColorBarclays's Etzer Darout raised their price target on Oruka Therapeutics (NASDAQ: ORKA) by 4.2% from $48 to $50 on 2026/03/13. The analyst maintained their Strong Buy rating on the stock. Oruka Therapeutics reported its Q4 and FY 2025 earnings. Raising their price target, Darout looked ahead and said they are positive on the name ahead of Phase 2 data next quarter, as ORKA-002 development continues to progress with a "clear benchmark" from Skyrizi." | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | a day ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to Premium? Sign In | ||||||
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.